At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
Escitalopramdrug
Likely dose
Escitalopram 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder, Adherence to Antiretroviral Therapy,Cognition, and Immune Status Among Patients With HIV and AIDS: A 6-week Open-label, Prospective, Pilot Trial.
In Brief
A Phase 3 clinical trial evaluating Escitalopram for Anxiety Disorders and HIV Infections. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate whether escitalopram is safe, well tolerated, and effective in the treatment of HIV-infected patients with generalized anxiety disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorders, HIV Infections
CountriesUnited States
CollaboratorsForest Laboratories
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartMay 2009
Primary CompletionSep 2009
Study CompletionSep 2010
TodayJul 2026
First PostedApr 24, 2009
Enrollment StartMay 1, 2009
Primary CompletionSep 1, 2009
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.2 years ago
Interventions
Escitalopramdrug
10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.